Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $69.8152W HIGH $148.83
Volume
454.69 K
Value Traded
98.06 M
Short % Float
8.65%
-5.15%Week
-26.26%1 Month
-37.03%3 Month
-30.16%6 Month
+951.64%5 Year
+951.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.66 B
EPS (TTM)
-5.25
P/E Ratio
-
Ent. Value
9.26 B
Total Shares
87.35 M
Float Shares
79.28 M
Insiders
9.42%
Institutions
54.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ABVX Catalyst Timeline
Dated clinical, regulatory and corporate events for Abivax SA
Catalyst Timeline
Dated clinical, regulatory & corporate events for Abivax SA
166Total events
21Upcoming
26Tier-1 (high impact)
2023 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Pre NDA MeetingObefazimodFDA Meeting
Positive Pre-NDA Interaction with FDA for obefazimod
ulcerative colitissource ↗
▲FDA Feedback ReceivedObefazimodFDA Meeting
Positive Pre-NDA Interaction with the FDA for obefazimod
Ulcerative Colitissource ↗
●Management ChangeCorporate
Strengthens Commercial Capabilities With Strategic Leadership Appointments
▼Equity OfferingCorporate
Full exercise of underwriters' option to purchase additional ADSs, bringing gross proceeds to $920M
▲Runway Guidance UpdateCorporate
Cash runway extended into Q2 2029 with net proceeds from offering
▼Equity OfferingCorporate
Launch of underwritten public offering of American Depositary Shares
▲Topline ReadoutObefazimodClinical Data
Positive ABTECT Maintenance Part 2 Results for Obefazimod
ulcerative colitissource ↗
●Oral PresentationObefazimodPresentation
Investor webcast discussing ABTECT Maintenance Part 2 results
ulcerative colitissource ↗
▲Primary Endpoint MetObefazimodClinical Data
Obefazimod met primary endpoint of clinical remission at Week 44 in Phase 3 ABTECT maintenance trial
moderately to severely active ulcerative colitissource ↗
●Oral PresentationObefazimodPresentation
Investor conference call to discuss topline results
moderately to severely active ulcerative colitissource ↗
▲Topline ReadoutObefazimodClinical Data
Landmark Phase 3 ABTECT Maintenance Trial Results
ulcerative colitissource ↗
▲Topline ReadoutObefazimodClinical Data
Landmark Phase 3 ABTECT Maintenance Trial Results
Ulcerative Colitissource ↗
▲Full ResultsObefazimodClinical Data
Three-year interim data from Study 108 open-label extension
ulcerative colitissource ↗
●Long Term DataObefazimodClinical Data
Three-Year Interim Data from Study 108 Open-Label Extension Trial
ulcerative colitissource ↗
◆Equity OfferingCorporate
Expected closing of ADS offering and repurchase of royalty certificates
▲Debt Royalty FinancingCorporate
Completed repurchase and cancellation of all outstanding royalty certificates
◆Poster PresentationObefazimodPresentation
Poster on mir-124 expression and cytokine reduction from ABTECT induction trials
moderately to severely active ulcerative colitissource ↗
◆Oral PresentationObefazimodPresentation
Oral presentation on histologic and combined histologic-endoscopic outcomes from ABTECT-1 and ABTECT-2
moderately to severely active ulcerative colitissource ↗
◆Poster PresentationObefazimodPresentation
Poster on efficacy in subgroups with prior inadequate response to advanced therapy from ABTECT phase 3 induction trials
moderately to severely active ulcerative colitissource ↗
◆Topline ReadoutObefazimodClinical Data
Topline results from 44-week maintenance trial expected in Q2 2026
moderate-to-severely active ulcerative colitissource ↗
●Trial CompletionObefazimodTrial
Completion of 44-week maintenance trial expected in Q2 2026
moderately to severely active ulcerative colitissource ↗
●Quarterly UpdateCorporate
Filing of Universal Registration Document with AMF and Annual Report (20-F) with SEC
▲DSMB ReviewObefazimodTrial
DSMB safety review completed with no new safety signals
ulcerative colitissource ↗
◆Oral PresentationObefazimodPresentation
Presented first evidence of anti-fibrotic activity and new clinical efficacy/safety analyses at ECCO 2026
inflammatory bowel diseasesource ↗
◆AbstractObefazimodPresentation
Oral presentation on preclinical anti-fibrotic activity of obefazimod at ECCO 2026
inflammatory bowel diseasesource ↗
◆Poster PresentationObefazimodPresentation
Multiple poster presentations on obefazimod from ABTECT Phase 3 induction trials at ECCO 2026
ulcerative colitissource ↗
◆Oral PresentationObefazimodPresentation
Oral presentation of obefazimod impact on fibrosis at ECCO 2026
Crohn's diseasesource ↗
◆Topline ReadoutObefazimodClinical Data
ABTECT 44-week maintenance top-line results
moderately to severely active ulcerative colitissource ↗
▲DSMB ReviewObefazimodTrial
ABTECT Phase 3 DSMB meeting found no new safety signals
ulcerative colitissource ↗
▲Runway Guidance UpdateCorporate
Cash runway into Q4 2027 based on EUR 589.7M cash as of September 30, 2025
▲Debt Royalty FinancingCorporate
Notified bondholders of intention to prepay in full outstanding balances of Tranches B and C of Kreos/Claret financing
▲Debt Royalty FinancingCorporate
Claret converted its portion of Tranche A OCABSA; no debt related to Tranche A remaining
▲Full ResultsObefazimodClinical Data
Patient-reported outcomes data from Phase 3 ABTECT induction trials
moderate-to-severely active ulcerative colitissource ↗
◆Oral PresentationObefazimodPresentation
Patient-reported outcomes data from Phase 3 ABTECT induction trials showing quality of life improvements
ulcerative colitissource ↗
▲Late-BreakerObefazimodPresentation
Late-breaking presentation of 8-week ABTECT induction trial results at UEG Meeting
moderate-to-severely active ulcerative colitissource ↗
◆Oral PresentationObefazimodPresentation
Oral presentation of obefazimod efficacy data in subsets of patients at UEG 2025
moderately to severely active ulcerative colitissource ↗
◆R&D DayObefazimodPresentation
Investor conference call to discuss topline results
moderate-to-severely active ulcerative colitissource ↗
◆Oral PresentationObefazimodPresentation
Efficacy and safety results from ABTECT-1 & 2 induction trials presented at UEG 2025
moderately to severely active ulcerative colitissource ↗
Past FDA Catalysts and PDUFA Decisions
How ABVX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | obefazimod (ABX464) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$1.3B
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 21%
Small Cap(rank 139 of 658)
Percentile Rank
Abivax SA carries a moderate pipeline score (48/100), with $2.1B risk-adjusted pipeline value, led by ABX464 in HIV Infection (Phase 2), across $65B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABX464 Small moleculeNCT05177835 | Ulcerative Colitis | Phase 3 | ACTIVE NOT_RECRUITING | 3,220 | Apr 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABVX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| obefazimod | refractory ulcerative colitis | Phase 3 | 2026-06-29 | clinical remission: 37.2%; endoscopic remission: 34.5%; relapse remission: 45.5%; EAIR malignancies excluding NMSC: all active combined 0.48 events per 100 PYs, 50 mg cohort 0.69 events per 100 PYs; EAIR NMSC: all active combined 0.95 events per 100 PYs, 50 mg cohort 0.69 events per 100 PYsRead More | Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety DatabaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABVX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 19.2 % (-6.8 %) | 800.60 M | 6.01 M | -7.3% ( -473.25 K) |
ABVX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABVX ranks across every disease it competes in
Competitive Position is a premium feature
See how ABVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABVX News
ABVXAbivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax announced that it will present seven scientific abstracts on obefazimod at the upcoming United European Gastroenterology Week 2026. The data will focus on the Phase 3 ABTECT trials for ulcerative colitis, long-term Phase 2 findings, and preclinical research. The presentations aim to highlight the drug's potential in treating inflammatory bowel disease.
Read more →ABVXAbivax Presents Business Updates and First Half 2026 Financial Results
Abivax has announced key business updates and financial results for the first half of 2026, highlighting a strong cash position and leadership changes to bolster commercialization efforts. Chris Rabbat will succeed Fabio Cataldi as Chief Medical Officer, while Tim Kelly has been appointed Chief Technical Officer. The company also completed a significant royalty certificate buy-back, enhancing its financial flexibility. Abivax is preparing for the potential commercialization of its lead drug candidate, obefazimod.
Read more →ABVXAbivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Abivax has successfully completed a positive pre-New Drug Application interaction with the FDA for obefazimod, aimed at treating moderately to severely active ulcerative colitis. The FDA provided constructive feedback, aligning with Abivax's planned NDA submission strategy. The company is on track to submit its NDA by the end of 2026.
Read more →ABVXAbivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
Abivax has announced the expansion of its Commercial Leadership Team with four new appointments aimed at enhancing its capabilities in preparation for the potential U.S. commercialization of obefazimod. The new leaders bring extensive experience in marketing, patient services, sales, and market access, which will be crucial for the planned NDA submission to the FDA in late 2026. This strategic move reflects Abivax's commitment to successfully launch its lead drug candidate for ulcerative colitis.
Read more →ABVXAbivax Announces Closing of $920 Million Public Offering
Abivax has announced the successful closing of a $920 million public offering of American Depositary Shares. The offering included the full exercise of underwriters' options, resulting in net proceeds of approximately $874.1 million. The company anticipates that these funds will support its operations through the fourth quarter of 2029.
Read more →ABVX▲ +9.1%on this newsshared move
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax has announced the full exercise of underwriters' option to purchase additional ADSs, resulting in total gross proceeds of approximately $920 million. The additional shares will be delivered alongside the closing of the offering, expected on July 6, 2026. The funds will primarily support the commercialization of obefazimod and ongoing clinical research.
Read more →ABVXCorrection: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax has announced the pricing of an upsized public offering of American Depositary Shares (ADSs) totaling $800 million, increased from the initial $600 million. The offering price is set at $125.00 per ADS, reflecting a 2.39% premium to the recent trading average. The proceeds are expected to support the commercialization of the drug candidate obefazimod and extend the company's cash runway into Q2 2029.
Read more →ABVXAbivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax SA has announced the resumption of trading of its ordinary shares on Euronext Paris. This follows a temporary halt due to a public offering of American Depositary Shares. The resumption is set for 3:30 p.m. CEST, allowing for investor allocations and pricing announcements. Abivax focuses on therapeutics for chronic inflammatory diseases, with its lead candidate in Phase 3 trials.
Read more →ABVXAbivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax has announced the pricing of its upsized public offering, raising $800M through the sale of 6.4 million American Depositary Shares at $125 each. The offering, which was increased from an initial $600M, is expected to extend the company's cash runway into Q2 2029, aiding in the commercialization of its lead drug candidate, obefazimod. The offering is set to close on July 6, 2026, subject to customary conditions.
Read more →ABVXAbivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announced a temporary halt in trading of its ordinary shares on Euronext Paris, effective from 9:00 a.m. CEST. This decision was made to facilitate the confirmation of allocations related to a public offering of American Depositary Shares. Trading is anticipated to resume later the same day at approximately 3:30 p.m. CEST.
Read more →ABVXAbivax Announces Launch of Public Offering of American Depositary Shares
Abivax has announced a public offering of approximately $600 million of American Depositary Shares. The funds raised are intended for the commercialization of its lead drug candidate, obefazimod, and for clinical research related to ulcerative colitis and Crohn's disease. The offering is subject to market conditions and may involve dilution for existing shareholders. Trading of the company's ordinary shares on Euronext is expected to be suspended temporarily during this process.
Read more →ABVX▲ +38.6%on this news· ran to +50% by day 3shared move
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
Abivax announced positive results from the ABTECT Maintenance Part 2 trial of obefazimod in refractory ulcerative colitis patients. The study demonstrated significant clinical benefits, including high remission rates among previously non-responding patients. The expanded safety database supports the drug's long-term safety profile, bolstering confidence ahead of a planned NDA submission.
Read more →ABVX▼ -44.1%on this news
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Abivax announced positive results from the Phase 3 ABTECT trial for obefazimod, showing significant efficacy in achieving clinical remission in patients with moderately to severely active ulcerative colitis. Both 25 mg and 50 mg doses met primary and secondary endpoints, indicating robust disease control. The drug also exhibited a favorable safety profile, with plans for an NDA submission to the FDA by late 2026.
Read more →ABVXAbivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax reported its first quarter 2026 financial results and shared interim data from Study 108, which indicates that 68% of patients with moderately to severely active ulcerative colitis achieved clinical remission after de-escalating their obefazimod dosage. The company has a cash position of €491.6 million, ensuring operational stability into late 2027. Upcoming results from the Phase 3 ABTECT trial are anticipated in late Q2 2026.
Read more →ABVXAbivax Annouces Results of its May 11, 2026 Annual General Meeting
Abivax reported the outcomes of its annual general meeting held on May 11, 2026, where all proposed resolutions were adopted by shareholders. This includes approval of the financial statements for the year 2025 and the compensation policy for key executives. The company, focused on chronic inflammatory disease therapies, is advancing its lead drug candidate, obefazimod, which is currently in Phase 3 trials for ulcerative colitis. Further details on the meeting's voting results will be made available on the company's website.
Read more →ABVXAbivax Announces Results of its May 11, 2026 Annual General Meeting
Abivax held its annual general meeting on May 11, 2026, where shareholders approved all resolutions proposed by the Board. This includes the financial statements for the 2025 financial year and the compensation policy for executives. The company continues to advance its lead drug candidate, obefazimod, in Phase 3 clinical trials for ulcerative colitis.
Read more →ABVX▲ +5.7%on this news
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Abivax announced the repurchase of royalty certificates and the pricing of a $45 million offering of American Depositary Shares (ADSs). The offering is expected to close on May 7, 2026, and aims to enhance the company's financial flexibility and support its clinical programs. The repurchase is part of a strategy to simplify the capital structure and strengthen the balance sheet.
Read more →ABVXAbivax to Present Data on Obefazimod at Digestive Disease Week
Abivax announced it will present nine abstracts on obefazimod at the upcoming Digestive Disease Week in Chicago. These presentations will focus on the Phase 3 ABTECT program, showcasing efficacy, safety, and patient-reported outcomes for patients with ulcerative colitis. The company's executives expressed confidence in obefazimod's ability to provide significant advancements in treatment. The findings are expected to enhance understanding of the drug's therapeutic potential in inflammatory bowel disease.
Read more →ABVXAbivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Abivax SA will hold its Annual Ordinary and Extraordinary General Meeting on May 11, 2026, in Paris. Shareholders are informed about relevant agenda items and resolutions, with detailed preparatory documents available per legal requirements. The company focuses on therapeutics aimed at regulating immune responses in chronic inflammatory diseases and is advancing its lead candidate, obefazimod, in Phase 3 trials for ulcerative colitis.
Read more →ABVXAbivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax SA has filed its Universal Registration Document with French regulators and its Annual Report with the U.S. SEC as of March 23, 2026. The documents contain the 2025 annual financial report and are available for public access on relevant websites. The company, focused on developing therapeutics for chronic inflammatory diseases, continues to advance its lead drug candidate, obefazimod, currently in Phase 3 trials for ulcerative colitis.
Read more →About Abivax SA
BIOPHARMAWATCH ELITE PLUS
Trade the next ABVX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime